VERTANICAL has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for VER-01, its investigational non-opioid treatment for chronic low back pain.
Regeneron Pharmaceuticals has signed a $2.32bn research collaboration with Parabilis Medicines to develop therapeutic candidates leveraging the latter’s Helicon peptide platform, with an emphasis on antibody-Helicon conjugates (AHCs).
Boehringer Ingelheim has received Japan’s Ministry of Health, Labour and Welfare (MHLW) approval for Jascayd (nerandomilast) to treat adults with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).
Arna Pharma and Slate Run Pharmaceuticals have completed a joint venture (JV) to form a speciality pharmaceutical company in the US focusing on branded products, 505(b)(2) medicines, and specialised generics.
Kyowa Kirin has received approval from the US Food and Drug Administration (FDA) for a dosing update to the prescribing information for Crysvita (burosumab-twza), introducing a new option for adults with X-linked hypophosphataemia (XLH).
Zydus Lifesciences (Zydus) is set to acquire all outstanding Assertio common shares in a deal valued at around $166.4m, through its subsidiary Zydus Worldwide DMCC.
Pfizer has received the European Commission’s (EC) marketing authorisation for expanding the approved Hympavzi (marstacimab) indication to treat haemophilia A or B with inhibitors in patients aged 12 years and above.
AI drug design and development company Isomorphic Labs has secured $2.1bn in Series B funding to expedite its transition from developing innovative AI models to deploying them on a larger scale.
GSK has entered an exclusive strategic partnership with SBP Group, via its subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ), to expedite the launch of bepirovirsen for chronic hepatitis B (CHB) patients in mainland China.
ACROBiosystems has upgraded its global licence solution for HEK293 functional cell lines, aimed at streamlining compliance to expedite biopharmaceutical research and development (R&D).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.